About Tobira Development (NASDAQ:TBRA)
Tobira Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The Company's product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of C-C chemokine receptor type 2 (CCR2) and C-C chemokine receptor type 5 (CCR5) in late stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure. CVC is also being investigated to address primary sclerosing cholangitis (PSC), a disease which causes inflammation and scarring of the bile ducts, eventually leading to liver damage. The Company's pipeline also includes evogliptin, a selective dipeptidyl peptidase 4 (DPP-4) inhibitor, which it plans to develop for NASH in combination with CVC.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on Assets-153.93%
Frequently Asked Questions for Tobira Development (NASDAQ:TBRA)
What is Tobira Development's stock symbol?
Tobira Development trades on the NASDAQ under the ticker symbol "TBRA."
How were Tobira Development's earnings last quarter?
Tobira Development Inc (NASDAQ:TBRA) announced its quarterly earnings results on Tuesday, August, 9th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by $0.08. The biopharmaceutical company had revenue of $1.06 million for the quarter, compared to the consensus estimate of $0.15 million. View Tobira Development's Earnings History.
Who are some of Tobira Development's key competitors?
Some companies that are related to Tobira Development include Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Medivation (MDVN), Kite Pharma (KITE), Exelixis (EXEL), bluebird bio (BLUE), Juno Therapeutics (JUNO), Neurocrine Biosciences (NBIX), Bioverativ (BIVV), Shire-Nps Pharmaceuticals (NPSP), TESARO (TSRO), BeiGene (BGNE), Sarepta Therapeutics (SRPT), GW Pharmaceuticals PLC (GWPH), Auspex Pharmaceuticals (ASPX), AveXis (AVXS) and Clovis Oncology (CLVS).
How do I buy Tobira Development stock?
Shares of Tobira Development can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tobira Development's stock price today?
One share of Tobira Development stock can currently be purchased for approximately $42.09.
How can I contact Tobira Development?
Tobira Development's mailing address is 701 Gateway Blvd Ste 200, SOUTH SAN FRANCISCO, CA 94080-7041, United States. The biopharmaceutical company can be reached via phone at +1-650-7416625.
MarketBeat Community Rating for Tobira Development (TBRA)MarketBeat's community ratings are surveys of what our community members think about Tobira Development and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Tobira Development (NASDAQ:TBRA) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Tobira Development (NASDAQ:TBRA)
Analysts' Ratings History for Tobira Development (NASDAQ:TBRA)
(Data available from 11/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/22/2016||Leerink Swann||Reiterated Rating||Outperform||$15.00 -> $45.00||N/A|
|9/21/2016||Cantor Fitzgerald||Downgrade||Buy -> Hold||$19.00 -> $42.00||N/A|
|8/13/2016||HC Wainwright||Reiterated Rating||Buy||$22.00 -> $31.00||N/A|
|8/10/2016||Cowen Inc||Reiterated Rating||Buy||$11.00||N/A|
Earnings History and Estimates Chart for Tobira Development (NASDAQ:TBRA)
Earnings History by Quarter for Tobira Development (NASDAQ TBRA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/9/2016||Q216||($0.63)||($0.71)||$0.15 million||$1.06 million||View||N/A|
Earnings Estimates for Tobira Development (NASDAQ:TBRA)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Tobira Development (NASDAQ:TBRA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Tobira Development (NASDAQ TBRA)
Insider Ownership Percentage: 6.20%
Institutional Ownership Percentage: 62.42%
Insider Trades by Quarter for Tobira Development (NASDAQ TBRA)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/31/2016||Pentwater Capital Management L||Major Shareholder||Buy||15,000||$41.84||$627,600.00|| |
|10/18/2016||Pentwater Capital Management L||Major Shareholder||Buy||40,000||$40.06||$1,602,400.00|| |
|10/17/2016||Pentwater Capital Management L||Major Shareholder||Buy||31,700||$40.07||$1,270,219.00|| |
|10/4/2016||Pentwater Capital Management L||Major Shareholder||Buy||4,481||$39.83||$178,478.23|| |
|9/29/2016||Pentwater Capital Management L||Major Shareholder||Buy||15,519||$39.49||$612,845.31|| |
|9/26/2016||Pentwater Capital Management L||Major Shareholder||Buy||50,000||$39.00||$1,950,000.00|| |
|9/23/2016||Pentwater Capital Management L||Major Shareholder||Buy||100,000||$39.19||$3,919,000.00|| |
|9/22/2016||Pentwater Capital Management L||Major Shareholder||Buy||1,624,200||$39.04||$63,408,768.00|| |
|7/13/2016||A/S Novo||Major Shareholder||Sell||59,067||$12.02||$709,985.34|| |
|7/7/2016||A/S Novo||Major Shareholder||Sell||92,119||$12.20||$1,123,851.80|| |
|6/30/2016||A/S Novo||Major Shareholder||Sell||66,814||$13.04||$871,254.56|| |
|6/6/2016||A/S Novo||Major Shareholder||Sell||187,500||$10.37||$1,944,375.00|| |
|3/4/2016||A/S Novo||Major Shareholder||Sell||190,000||$6.80||$1,292,000.00|| |
|11/18/2015||A/S Novo||major shareholder||Sell||225,000||$9.79||$2,202,750.00|| |
|5/4/2015||A/S Novo||Major Shareholder||Buy||838,041||$10.62||$8,899,995.42|| |
|5/4/2015||Parters Vii L P Domain||Major Shareholder||Buy||277,777||$10.62||$2,949,991.74|| |
|4/16/2014||Robert Kierlin||major shareholder||Buy||575,000||$6.00||$3,450,000.00|| |
|2/5/2014||Robert Kierlin||major shareholder||Buy||400,000||$5.00||$2,000,000.00|| |
|8/27/2013||Raphael Wisniewski||Director||Buy||1,215,708||$4.00||$4,862,832.00|| |
|8/27/2013||Rmi Investments S.A.R.L.||Major Shareholder||Buy||3,866,529||$4.00||$15,466,116.00|| |
Latest Headlines for Tobira Development (NASDAQ TBRA)
|Financial Contrast: Tobira Development (TBRA) vs. The Competition|
www.americanbankingnews.com - September 18 at 8:34 PM
|Sarepta Therapeutics (SRPT) and Tobira Development (TBRA) Financial Contrast|
www.americanbankingnews.com - September 7 at 12:06 AM
|Tobira Therapeutics (NASDAQ:TBRA) vs. Radius Health (RDUS) Head to Head Contrast|
www.americanbankingnews.com - July 15 at 6:20 PM
|The Lesson in Straight Path's Short Squeeze|
www.bloomberg.com - May 11 at 11:06 PM
|Biotech Forum Daily Digest: Upward Resistance Levels Continue To Hold; Spotlight On Foamix Pharmaceuticals|
seekingalpha.com - March 4 at 1:11 AM
|Allergan Hints It Is Ready to Make a Splash for More Near-term Growth|
us.rd.yahoo.com - January 11 at 5:38 AM
|Biotech Stocks on Investors' Radar -- Agenus, Portola Pharma, Tobira Therapeutics, and Auris Medical - PR Newswire (press release)|
www.prnewswire.com - November 1 at 12:21 PM
|TOBIRA THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisiti|
biz.yahoo.com - November 1 at 12:21 PM
|Notable Thursday Option Activity: TBRA, CRUS, BCOR - Nasdaq|
www.nasdaq.com - October 28 at 11:39 AM
|Notable Thursday Option Activity: TBRA, CRUS, BCOR|
www.nasdaq.com - October 27 at 7:46 PM
|Allergan CEO Brent Saunders Succeeds Paul Bisaro as Chairman|
www.wsj.com - October 26 at 7:37 PM
|Tobira Therapeutics (TBRA) Presents Phase 2b CENTAUR Year 1 Analysis at AASLD Annual Meeting|
www.streetinsider.com - October 20 at 7:55 PM
|Tobira Therapeutics Announces Late-Breaking Oral...|
www.benzinga.com - October 20 at 12:45 PM
|Allergan (AGN) Announces Early HSR Act Termination in Proposed Merger with Tobira|
www.streetinsider.com - October 19 at 7:13 PM
|FTC Grants Early Termination Of HSR Waiting Period For Allergan-Tobira Deal|
www.nasdaq.com - October 19 at 10:50 AM
|Controversy Over Allergan's 500% Premium for Tobira Looks Overdone|
www.thestreet.com - October 12 at 7:35 PM
Financials are not available for this stock.
Tobira Development (NASDAQ TBRA) Chart for Friday, November, 24, 2017